Summary of Significant Accounting Policies - Summary of Revenue and Adjusted EBITDA by Segment (Detail) - USD ($) $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|||
| Segment Revenue | |||||
| Total revenue | $ 243,920 | $ 305,463 | $ 440,900 | ||
| Segment Adjusted EBITDA | |||||
| Total Adjusted EBITDA | (76,525) | (147,188) | (141,391) | ||
| Reconciliation of net loss to Adjusted EBITDA | |||||
| Net loss | (183,619) | (250,863) | (183,533) | ||
| Interest (income), net | (255) | (6,244) | (5,269) | ||
| Other (income) / expense, net | (1,322) | (1,340) | 19 | ||
| Depreciation and amortization | 20,246 | 22,610 | 9,901 | ||
| Stock-based compensation expense | 88,425 | 44,838 | 37,491 | ||
| Restructuring and other charges | [1] | 44,692 | |||
| Unallocated Corporate [Member] | |||||
| Segment Adjusted EBITDA | |||||
| Total Adjusted EBITDA | (30,587) | (28,460) | (23,793) | ||
| Consumer & Research Services [Member] | |||||
| Segment Revenue | |||||
| Total revenue | 243,866 | 299,907 | 437,919 | ||
| Segment Adjusted EBITDA | |||||
| Total Adjusted EBITDA | 12,796 | (65,845) | (85,822) | ||
| Therapeutics [Member] | |||||
| Segment Revenue | |||||
| Total revenue | 54 | 5,556 | 2,981 | ||
| Segment Adjusted EBITDA | |||||
| Total Adjusted EBITDA | $ (58,734) | $ (52,883) | $ (31,776) | ||
| |||||